BeiGene Stock (OTC:BEIGF), Trade Ideas

BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.

BeiGene Ltd

The Dow Jones index closed higher by over 250 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#8217;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">Conn&#8217;s</h3>
<ul>
<li>The Trade: Conn&#8217;s, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CONN#NASDAQ">CONN</a>) Director Douglas H Martin <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 10,817 shares</a> at an average price of $3.71. To acquire these shares, it cost around $40,103.</li>
<li>What's Happening: On April 11, the company reported fourth-quarter adjusted earnings per share of $(1.25) loss, narrower than the street view of $(1.57).</li>
<li>What Conn&#8217;s Does: Conn&#8217;s Inc is a US-based specialty retailer selling durable consumer goods and related services.</li>
</ul>
<h3 class="wp-block-heading">Mobile Infrastructure</h3>
<ul>
<li>The Trade: Mobile Infrastructure Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEEP#NYSE">BEEP</a>) CEO Manuel Chavez III <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 5,442 shares at</a> an average price of $3.44. To acquire these shares, it cost around $18,720.</li>
<li>What's Happening: Mobile Infrastructure is expected to issue its first quarter 2024 earnings release on May 15, 2024.</li>
<li>What Mobile Infrastructure Does: Mobile Infrastructure Corp focuses on acquiring, owning, and leasing parking facilities and related infrastructure, including parking lots, parking garages and other parking structures throughout the United States.</li>
</ul>
<h3 class="wp-block-heading">Alzamend Neuro</h3>
<ul>
<li>The Trade: Alzamend Neuro, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALZN#NASDAQ">ALZN</a>) Director Milton C Ault III <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 1,000 shares</a> at an average price of $0.69. The insider spent around $688 to buy those shares.</li>
<li>What's Happening: On Dec. 11, 2023, Alzamend Neuro received a &#8220;Study May Proceed&#8221; letter from the FDA for the initiation of study AL001-PTSD01, a Phase 2A study of AL001 for post-traumatic stress disorder (PTSD).</li>
<li>What Alzamend Neuro Does: Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/04/38396543/meta-likely-to-report-higher-q1-earnings-here-are-the-recent-forecast-changes-from-wall-streets-mos">Meta Likely To Report Higher Q1 Earnings; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a>

Long Ideas

News

Penny Stocks

Insider Trades

Markets

Trading Ideas

ALZN

Mobile Infrastructure Corporation Common Stock

BEEP

CONN

Alzamend Neuro And 2 Other Stocks Under $5 Insiders Are Buying

<ul>
<li>Continue to expect total revenue to decline by a low- to mid-single digit percentage vs. 2023 and expect core pharmaceutical revenue (product revenue + LEQEMBI) to be flat vs. 2023</li>
<li>Continue to expect operating income to grow low-double digit percentage vs. 2023 with expected midsingle digit percentage point operating margin improvement</li>
</ul>

Biotech

Earnings

Guidance

Health Care

General

BIIB

Biogen Reaffirms 2024 Adjusted EPS Guidance Of $15.00-$16.00, Representing EPS Growth Of Approximately 5% Versus 2023 At The Mid-point Versus Consensus Of $15.48

Excluding an estimated&nbsp;$0.40&nbsp;per share impact of restructuring charges and other items, the company continues to expect 2024 adjusted earnings per share of&nbsp;$9.00&nbsp;to&nbsp;$9.50.

Avery Dennison Corporation Lowers FY24 Guidance Range For Reported Earnings Per Share From $8.65-$9.15 To $8.60-$9.10

B of A Securities analyst Andrew Obin initiates coverage on GE Vernova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) with a Neutral rating and announces Price Target of $150.

Price Target

Initiation

Analyst Ratings

B of A Securities Initiates Coverage On GE Vernova with Neutral Rating, Announces Price Target of $150

Earnings Beats

BXMT

Blackstone Mortgage Trust Q1 2024 Distributable EPS Prior To Charge-Offs $0.65 vs $0.43 Estimate

MAG Silver Announces That Juanicipio Processed 325,684 Tonnes Of Ore In Q1

Guggenheim analyst Joseph Osha downgrades Enphase Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) from Neutral to Sell and announces $92 price target.

Downgrades

ENPH

Guggenheim Downgrades Enphase Energy to Sell, Announces $92 Price Target

Evercore (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVR#NYSE">EVR</a>) reported quarterly earnings of $2.13 per share which beat the analyst consensus estimate of $2.09 by 1.91 percent. This is a 1.39 percent decrease over earnings of $2.16 per share from the same period last year. The company reported quarterly sales of $587.328 million which missed the analyst consensus estimate of $636.381 million by 7.71 percent. This is a 1.65 percent increase over sales of $577.782 million the same period last year.

Earnings Misses

Evercore Q1 2024 Adj EPS $2.13 Beats $2.09 Estimate, Sales $587.328M Miss $636.381M Estimate

Baird analyst Eric Coldwell maintains Medpace Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) with a Outperform and raises the price target from $446 to $454.

MEDP

Baird Maintains Outperform on Medpace Hldgs, Raises Price Target to $454

Lennox Reaffirms FY24 Revenue Guidance Of Approximately 7%, With 2% Of Benefit From AES Acquisition; Revises EPS Guidance From $18.50-$20.00 To $19.00-$20.00, Est $19.72

HELE

Helen Of Troy Sees FY25 Adj EPS Of $8.70-$9.20 Vs. $9.72 Est.

CNX Resources And Deep Well Services Announced A Joint Venture To Launch AutoSepSM Technologies, A New Oilfield Service Company Providing Step Change Improvement To Conventional Flowback Operations

Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) reported quarterly earnings of $3.67 per share which beat the analyst consensus estimate of $3.44 by 6.69 percent. This is a 7.94 percent increase over earnings of $3.40 per share from the same period last year. The company reported quarterly sales of $2.291 billion which missed the analyst consensus estimate of $2.311 billion by 0.87 percent. This is a 7.00 percent decrease over sales of $2.463 billion the same period last year.

Biogen Q1 2024 Adj EPS $3.67 Beats $3.44 Estimate, Sales $2.291B Miss $2.311B Estimate

Baird analyst Catherine Schulte maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Outperform and raises the price target from $259 to $271.

Baird Maintains Outperform on Danaher, Raises Price Target to $271

Helen Of Troy Sees FY25 $1.965B - $2.025B Vs. $2.04B Est.

Avery Dennison (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVY#NYSE">AVY</a>) reported quarterly earnings of $2.29 per share which beat the analyst consensus estimate of $2.15 by 6.51 percent. This is a 34.71 percent increase over earnings of $1.70 per share from the same period last year. The company reported quarterly sales of $2.15 billion which met the analyst consensus estimate. This is a 4.16 percent increase over sales of $2.06 billion the same period last year.

Avery Dennison Q1 Adj $2.29 Beats $2.15 Estimate, Sales $2.15B Inline

On Tuesday, April 23rd, the U.S. stock markets closed higher, boosted by strong earnings from major companies and interest in&nbsp;key&nbsp;growth stocks.&nbsp;
Tesla launched new EV models and reported lower-than-expected revenue,&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/04/38394792/tesla-stock-surges-despite-ugly-q1-results-heres-why" rel="noreferrer noopener">yet its stock surged 6% after hours</a>.
According to the economic data, the S&amp;P Global composite PMI dropped to 50.9 in April from 52.1 last month. Meanwhile, new single-family home sales rose 8.8% in March to an annualized rate of 693,000, rebounding from a 5.1% drop in February.
Ten of the 11 S&amp;P 500 sectors advanced, with notable gains in the communication services and technology sectors. However, the Materials sector declined.
The Dow Jones Industrial Average gained 0.69% to close at 38,503.69. The S&amp;P 500 rose 1.20%, ending the day at 5,070.55, while the Nasdaq Composite climbed 1.59%, finishing the session at 15,696.64.
Asian Markets Today
<ul>
<li>On Wednesday, Japan&#8217;s Nikkei 225 index finished the trading day higher by 2.26% at 38,410.50, led by gains in the Power, Gas &amp; Water, and Transportation Equipment sectors.</li>
<li>The Japanese stock market ended significantly higher on Wednesday, extending its winning streak to three days; the rally&nbsp;was fueled&nbsp;by positive sentiment from Wall Street&#8217;s overnight gains, driven by strong corporate earnings.</li>
<li>In Australia, the S&amp;P/ASX 200 closed slightly lower by 0.01% at 7,683.00, led by losses in the Utilities, Industrials and IT sectors.</li>
<li>India&#8217;s Nifty 50 closed higher by 0.20% at 22,413.05, and the Nifty 500 rose 0.41%, closing at 20,736.90.</li>
<li>China&#8217;s Shanghai Composite gained 0.76% to end the session at 3,044.82, and the Shenzhen CSI 300 rose 0.44%, closing at 3,521.62.</li>
<li>Hong Kong&#8217;s Hang Seng Index gained 2.21%, concluding the day at 17,201.27.</li>
</ul>
Eurozone at 06:15 AM ET
<ul>
<li>The European STOXX 50 index was up 0.40%.</li>
<li>Germany&#8217;s DAX gained 0.25%.</li>
<li>France&#8217;s CAC increased 0.42%.</li>
<li>U.K.&#8217;s FTSE 100 traded higher by 0.57%.</li>
</ul>
Commodities at 06:15 AM ET
<ul>
<li>Crude Oil WTI was trading lower by 0.44 % at $82.99/bbl, and Brent was down 0.09% at $87.08 bbl.</li>
<li>Natural Gas gained 0.62% to $2.107.</li>
<li>Gold was trading lower by 0.49% at $2,330.60, Silver declined 0.58% to $26.203, while Copper was up 0.76% at $4.4685.</li>
</ul>
US Futures at 06:15 AM ET&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Dow futures were down 0.05%, S&amp;P 500 futures rose 0.08%, and Nasdaq 100 Futures climbed 0.48%.
Forex at 06:15 AM ET
The U.S. dollar index rose 0.17% to 105.58, the USD/JPY rose 0.06% to 154.91, and the USD/AUD declined 0.26% to 1.5378.
Photo by Pavel Bobrovskiy via Shutterstock

Asia

Emerging Markets

Eurozone

Futures

Commodities

Forex

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Asia And Europe Markets Rise, US Dollar Rebounds - Global Markets Today While US Slept

Helen Of Troy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HELE#NASDAQ">HELE</a>) reported quarterly adjusted earnings of $2.45 per share which beat the analyst consensus estimate of $2.30 by 6.52 percent. This is a 21.89 percent increase over earnings of $2.01 per share from the same period last year. The company reported quarterly sales of $489.20 million which beat the analyst consensus estimate of $476.90 million by 2.58 percent. This is a 0.95 percent increase over sales of $484.58 million the same period last year.

Helen Of Troy Q4 Adj $2.45 Beats $2.30 Estimate, Sales $489.20M Beat $476.90M Estimate

Lennox Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LII#NYSE">LII</a>) reported quarterly Adj earnings of $3.47 per share which beat the analyst consensus estimate of $3.16 by 9.81 percent. The company reported quarterly sales of $1.047 billion which missed the analyst consensus estimate of $1.050 billion by 0.33 percent. This is a 0.19 percent decrease over sales of $1.049 billion the same period last year.

Lennox Intl Q1 2024 Adj EPS $3.47 Beats $3.16 Estimate, Sales $1.047B Miss $1.050B Estimate

Baird analyst Craig Kennison maintains Polaris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PII#NYSE">PII</a>) with a Outperform and lowers the price target from $110 to $100.